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ABSTRACT
Introduction Evidence suggests that the rate of 
cardiovascular implantable electronic device (CIED) 
infections is increasing more rapidly than the rates of CIED 
implantation and is associated with considerable mortality, 
morbidity and health economic impact. Antimicrobial 
surface treatments are being developed for CIEDs to 
reduce the risk of postimplantation infection within the 
subcutaneous implant pocket.
Methods and analysis The feasibility of processing 
cardiac pacemakers with the Agluna antimicrobial silver 
ion surface technology and in vivo biocompatibility 
were evaluated. Antimicrobially processed (n=6) 
and control pacemakers (n=6) were implanted into 
subcutaneous pockets and connected to a part of the 
sacrospinalis muscle using an ovine model for 12 weeks. 
Pacemaker function was monitored preimplantation and 
postimplantation.
Results Neither local infection nor systemic toxicity 
were detected in antimicrobial or control devices, and 
surrounding tissues showed no abnormal pathology or 
over-reactivity. Semiquantitative scores of membrane 
formation, cellular orientation and vascularity were 
applied over five regions of the pacemaker capsule and 
average scores compared. Results showed no significant 
difference between antimicrobially processed and control 
pacemakers. Silver analysis of whole blood at 7 days 
found that levels were a maximum of 10 parts per billion 
(ppb) for one sample, more typically ≤2 ppb, compared 
with <<2 ppb for preimplantation levels, well below 
reported toxic levels.
Conclusions There was no evidence of adverse or 
abnormal pathology in tissue surrounding antimicrobially 
processed pacemakers, or deleterious effect on basic 
pacing capabilities and parameters at 12 weeks. This 
proof of concept study provides evidence of basic 
biocompatibility and feasibility of applying this silver 
ion-based antimicrobial surface to a titanium pacemaker 
surface.
INTRODUCTION
An increasing number of cardiac devices 
are being implanted globally each year, 
including implantable loop recorders, 
permanent pacemakers, implantable cardio-
verter-defibrillators (ICDs) and cardiac 
resynchronisation therapy (CRT) devices 
(collectively termed cardiovascular implant-
able electronic devices(CIEDs)).
Implantation rates are rising for two reasons: 
an increase in the range of clinical indica-
tions for which CIEDs have been approved 
and also the fact that the population is ageing 
and therefore demand is greater. Although 
the use of a CIED is associated with a lower 
risk of death and a better quality of life, the 
KEY MESSAGES
What is already known about this subject?
An increasing number of cardiac devices are being 
implanted globally each year, which are collectively 
known as cardiovascular implantable electronic 
devices (CIEDs). Although the use of a CIED is 
associated with a lower risk of death and a better 
quality of life, the onset of a postoperative device-
related infection can lead to devastating and costly 
clinical complications. Recent data suggest that the 
rate of CIED infection may be rising faster than the rate 
of CIED implantation. Approaches are therefore being 
investigated to reduce the risk of such infections.
What does this study add?
This study demonstrates the feasibility of processing 
cardiac pacemakers with the silver ion-based Agluna 
surface technology and in vivo biocompatibility. By 
treating the cardiac pacemaker as an integral part of 
the manufacturer’s standard manufacturing processes, 
it avoids the use of approaches such as antibiotic-
loaded pouches or the application of topical agents at 
the time of surgery.
How might this impact on clinical practice?
The key aim of this approach is to reduce the risk of 
infection in the first 3–6 months, following surgical 
implantation of the CIED. This will improve patient 
outcomes and reduce the cost of treating infections 
associated with such procedures. By treating the 
device surface as an integral part of the manufacturer’s 
standard manufacturing processes, it reduces the time 
and procedural complexity of other approaches.
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onset of a postoperative device-related infection can lead 
to devastating and costly clinical complications.1 Histor-
ically, reported rates of these infections range from 0% 
to as high as 20%1 in some series. However, recent data 
suggest that the rate of CIED infection may be rising faster 
than the rate of CIED implantation.1 As well as causing 
considerable morbidity and prolonged hospitalisation, 
mortality rates remain high and the economic burden 
of CIED infection management is high, both for patients 
and third-party payers.1–5 There are a number of studies 
examining the cost of combined medical and surgical 
treatment of CIED-related infections, indicating that 
cost typically varies between US$25 000 for permanent 
pacemakers and US$50 000 for ICD and CRTs.4 6–8 A US 
retrospective study8 of 200 219 Medicare patients (2007 
calendar year) reported 5817 admissions for infection as 
well as significant increases in mortality (admissions and 
long term) and length of stay depending on CIED type. 
The standardised, adjusted total admission cost ranged 
between US$28 676 for pacemakers and US$53 349 for 
complex devices (Cardiac Resynchronisation Therapy 
Defibrillator CRT-D, or a Cardiac Resynchronisation 
Therapy Pacemaker (CRT-P)and ICDs). Costs of intensive 
care, length of stay and supplies, including replacement 
CIED, were the highest proportion of the costs. The 
standardised, adjusted incremental cost was between 
US$14 360 and US$16 498 depending on CIED type.
The purpose of this study was to evaluate the biocom-
patibility of a silver ion-based antimicrobial surface 
technology applied to the outer can of a pacemaker and 
its impact on basic pacemaker function. The study would 
also provide an opportunity to examine for signs of any 
in vivo bacterial colonisation or infection associated with 
implantation. The study was not designed to evaluate 
any specific antimicrobial effect or powered to detect a 
reduction in infection rate.
FEASIBILITY OF ANTIMICROBIAL SURFACE PROCESSING OF 
PACEMAKERS
The Agluna antimicrobial surface is produced by an 
advanced electrochemical process, developed and owned 
by Accentus Medical, Oxfordshire, UK. The process relies 
on an anodising technique that forms a passive layer inte-
gral to the surface and is primarily applicable to medical 
devices manufactured from titanium and its alloys. The 
process creates 3–5 µm diameter reservoirs in the surface 
of the implant that contains amorphous hydrous titania. 
Silver ions (Ag+) are incorporated into the surface by ion 
exchange primarily into the hydrous titania. The Ag+ ions 
inhibit the local colonisation of pathogens on the device 
surface and hence the formation of biofilm, while also 
eluting in a controlled manner into the local environment 
during the critical weeks and months of the postoperative 
period, reducing the risk of localised infection. A number 
of in vitro studies have been performed to demonstrate 
the safety and efficacy of the approach. The efficacy has 
been shown against a number of Gram-positive bacteria 
(eg, Staphylococcus aureus and Staphylococcus epidermidis), 
Gram-negative bacteria (eg, Pseudomonas aeruginosa) and 
fungi (eg, Candida albicans) commonly associated with 
medical device-related infections. This antimicrobial 
surface is in clinical use, applied to custom limb salvage 
orthopaedic implants and a CE mark-approved Modular 
Endoprosthetic Tumour System (METS), both distrib-
uted by Stanmore Implants Worldwide, Elstree, UK, 
which replace large segments of resected bone. Studies 
report greater than 50% reduction in infection in this 
high-risk patient cohort as well as a number of additional 
observed clinical benefits.9 10
Initial feasibility of antimicrobial surface processing 
of cardiac devices was assessed prior to this in vivo 
evaluation phase, by processing a series of explanted 
pacemakers (after pacemaker generator change) with 
the antimicrobial technology and assessing the effect on 
pacing and residual battery function. This work showed 
no deleterious effect on the basic pacing function of the 
pacemaker, and demonstrated that this antimicrobial 
surface would be feasible for subsequent evaluation of in 
vivo biocompatibility and device function.
OBJECTIVES OF IN VIVO EVALUATION
The objective of this in vivo study was to determine 
whether antimicrobial surface processing of the titanium 
surface of cardiac pacemakers would alter local, soft 
tissue biocompatibility compared with control implants. 
The study would also allow assessment of biofilm inci-
dence, seen as precursor to implantable device infection. 
In addition, this study would confirm whether pacemaker 
function could be maintained in vivo, prior to any possible 
clinical evaluation. To enable an accurate comparison, 
antimicrobial surface processed and non-processed 
control pacemakers were implanted in the same control 
subjects. The antimicrobial surface was not applied to 
the pacing leads primarily as the process involves an 
anodising technique that is only applicable to medical 
devices consisting of titanium, tantalum or zirconia (and 
their alloys). There are studies that report metal-cata-
lysed degradation of polyurethane.11 The conductor is 
often a nickel/cobalt/chromium/molybdenum alloy 
with elements added to improve conductivity such as a 
silver core.12 The degradation is most likely due to the 
catalytic reduction of hydrogen peroxide to water at 
the silver metal surface, which then by direct electrical 
contact with the conductor is able to increase the rate 
of galvanic corrosion. This leads to an increase in the 
concentration of transition ions locally, and accelerated 
hydroxyl radical production, by well-known interaction 
with hydrogen peroxide, resulting in further polyure-
thane degradation. Electrical isolation is therefore the 
recommended approach to eliminate unwanted galvanic 
corrosion. The silver used in this antimicrobial surface 
is in the form of adsorbed silver ions incorporated into 
the semiconductor oxide film, which is not in electrical 
contact with the conductor and so will not be able to drive 
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Table 1 Implants used
Supplier Model
Number 
supplied
Agluna 
processed
Boston Scientific Altrua 20 SSIR-1 4 2
Medtronic Adapta ADSR01 4 2
St Jude Zephyr XL SR 2 1
Sorin Reply SR 2 1
the accelerated galvanic corrosion, leading to degrada-
tion of the polyurethane. This reduces the possibility of 
significant deleterious effect on the polyurethane-coated 
leads that may also be located in the device pocket.
MATERIALS AND METHODS
Experimental in vivo protocol
An ethics committee-approved ovine model was used 
to test the in vivo performance of these devices. In our 
model, antimicrobial surface processed and non-pro-
cessed control pacemakers were implanted at the same 
procedure between muscles in the back, on either side 
of the spine of the same sheep to maximise the compar-
ison potential for the animals to act as their own controls. 
To provide considerable confidence for future human 
studies and simulate natural bacterial colonisation condi-
tions, follow-up of the animals was continued for 12 
weeks (84 days). Although by design, this study was not 
Good Laboratory Practice (GLP) compliant, the implan-
tation was performed in a GLP-approved facility at the 
Royal Veterinary College, Hertfordshire, UK. Therefore, 
the implantation procedure, the in-life phase and the 
retrieval of implants followed GLP guidelines and was 
ethics committee approved. The antimicrobial surface 
process was only applied to the outer pacemaker tita-
nium casing and not to any other component, such as the 
device header or the leads. To ensure comparison of anti-
microbial processed devices for leading manufacturers, 
12 single chamber (VVI) pacemakers and corresponding 
electrodes were purchased from the four  most common 
UK manufacturers, as shown in table 1, and pacing 
programmers utilised for the duration of the study. This 
enabled us to physically and closely simulate human 
conditions where various pacemaker generators of 
differing sizes and shapes are used, with differing final 
pacemaker construction.
The surface of six cardiac pacemaker outer titanium 
casings was antimicrobially processed by Accentus 
Medical and then resterilised using ethylene oxide 
(Andersen Caledonia, Bellshill, UK) and packed ready 
for implantation (the manufacturers supplied control 
sterile pacemakers). The corresponding control pace-
makers were not handled in any other way, other than 
externally testing pacing parameters including battery 
life and pacing impedance. Pacemaker function was 
tested preimplant while in the packaging (and for test 
generator models, postantimicrobial processing and 
preimplant). Threshold testing was done manually to 
see and feel muscle contraction at 60 beats per minute 
and then at 10 V to confirm no other adverse reactions in 
VOO pacing mode, as striated muscle signals could not 
be detected while the animal was under anaesthesia. The 
same pacing and threshold tests were performed for each 
pacemaker. By design, there was no intention nor ethical 
approval to pace the heart in this study.
Implantation
The day of surgery was referred to as S0. Prior to surgery, 
blood samples were taken to determine baseline levels 
of silver, and clotted and non-clotted blood samples 
were stored at −73°C until required. At surgery, a dorsal, 
longitudinal incision measuring ~5 cm was made, posi-
tioned ~3 cm to either side of the spine. The underlying 
fascia was dissected and the dorsal surfaces of sacrospi-
nalis muscle were accessed by further blunt dissection. 
After confirming access to muscle, the electrode was 
placed on the muscle with the pacing tip at least 5 cm 
or more away from the pacemaker pocket space, and 
then connected to the pacemaker generator. The pace-
maker was positioned on the surface of the muscle, 
away from the tip, with spare electrode coiled below the 
generator, simulating human implantation conditions 
other than the electrode not being placed via vessels 
into the heart. A non-resorbable suture was used to tie 
the pacemaker electrode in place, around the provided 
sleeves. There was surprisingly good space above the 
muscle and the thick fat layers to place the pacemaker 
comfortably without causing any non-smooth pocket 
profiles or risk of erosion against vertebral or thoracic 
bones. The wound was closed in three layers with resorb-
able sutures. This procedure was repeated on the other 
side of the spinal column. In all cases, the left-hand side 
received a control pacemaker first, and the right-hand 
side received the antimicrobially processed pacemaker, 
with sterile conditions maintained on both sides. Two 
experienced veterinarian surgeons performed the 
procedures with an experienced pacing cardiologist 
in theatre to programme, activate and test the pacing 
function (preprocedure, periprocedure and postpro-
cedure), and test electrode thresholds and impedance 
as well as confirm muscle contraction. Each procedure 
took about 25 min, with separate aseptic techniques for 
both procedures on each sheep under general anaes-
thesia. Pacemakers were also activated postanaesthesia 
to visualise muscle contraction, but then left inactive to 
avoid animal discomfort. Intermittent pacing activations 
were made to check pacing threshold in both bipolar 
mode and unipolar mode confirming required function. 
Antibiotics were administered in compliance with ethical 
approval and study protocols. This is standard practice 
in this study model and no effect on wound healing or 
end point was anticipated. Animals were then returned 
to individual pens. During this extensive experimental 
condition, animals were observed weekly for operative 
healing, infection symptoms and reactions externally. 
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Figure 1 Radiographs of in situ pacemakers control (A) and 
antimicrobially processed surface (B).
Figure 2 Retrieval photographs (A–C) from around a control Sorin Reply SR.
Blood samples were taken on days S0, S7, S14, S28, S56 
and S84 and stored in a freezer.
Implant retrieval
After sacrifice with an overdose of sodium pentobarbi-
tone, animals were positioned in sternal recumbency, 
and a radiograph was taken to determine the position 
of the pacemaker. Using the same sterile conditions 
and operating conditions as during implant, the pacing 
pockets were entered using aseptic technique, creating 
a new incision just dorsal to the original incision site. 
Wound healing was assessed prior to incision and pace-
makers checked for migration and activated to check 
parameters and muscle contraction. Digital photography 
records were undertaken throughout the surgeries, 
including prior to entering the pacemaker capsules and 
after exposing the implant pocket sites. The soft tissue 
surrounding the pacemaker was isolated. If a fluid-filled 
pocket had formed, then the fluid was aseptically aspi-
rated and samples sent for microbiological assessment. 
The soft tissue surrounding the pacemaker was breached 
with a sterile scalpel and a swab stick inserted through 
the opening and manipulated over the surface of the 
pacemaker and the adjacent soft tissue. The swab was 
sent off for microbiological assessment, examining for 
bacterial isolates after 48 hours aerobic and anaerobic 
incubation. Samples of the tissue surrounding the pace-
maker were taken and frozen at −73°C and sent for silver 
measurement by inductively coupled plasma mass spec-
troscopy (ICP-MS), where required. Pacing generators 
and electrodes were stored separately in sterile zip-locked 
bags and photographed for biofilm formation. Other 
samples of surrounding tissue were taken and processed 
for paraffin wax embedded histology. Samples of spleen, 
heart, liver, kidney and lungs were fixed in formal saline 
and retained.
The measurement of inflammation was blinded, 
based on an assigned code, which was disclosed only 
after the analysis and performed by two independent 
analysts. This used a semiquantitative scoring system 
for membrane formation, cellular orientation and 
vascularity. As the data were not normally distrib-
uted, as confirmed by Kolmogorov–Smirnov test, a 
non-parametric Mann-Whitney U test comparing two 
independent variables was used, where p <0.05 was 
considered to be significant. The number of macro-
phages in the capsule surrounding the implants was 
estimated by counting cells in a 10× objective field of 
view, in 10 different regions. A comparison was made 
with tissue surrounding control implants and anal-
ysed using energy dispersive X-ray (EDX) analysis to 
determine the amount of silver within the surrounding 
tissues. Two of the antimicrobially processed pace-
makers were taken and examined under scanning 
electron microscopy–EDX for silver content. The 
retrieved pacemakers were assessed to check that 
they were working appropriately again after removal 
from the sheep, confirming battery and program-
ming parameters only. All electrode material was also 
removed. Residual silver measurement on the antimi-
crobially processed pacemakers was then performed 
using acid extraction and ICP-MS.
RESULTS
Figure 1 indicates the position of the Sorin Reply SR 
pacemakers on radiographs confirming the implants 
have remained in place during the 12-week period of 
insertion.
The appearance of the tissue surrounding the implant 
and the capsule where it was located was consistent. In 
some cases, capsules displayed slight evidence of inflam-
mation but were all well vascularised. All pacemakers 
could easily be removed, without any tissue remaining 
attached to its surface, leaving an imprint on the tissue 
surface, with little evidence of inflammation. By way of 
example, figure 2 shows postmortem photographs of a 
control Sorin Reply SR pacemaker being retrieved; clearly 
a fibrous tissue membrane, which is translucent, covers 
the pacemakers on its dorsal surface. This membrane 
appears to be relatively avascular with little evidence of 
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Figure 3 Retrieval photographs (A–C) from around an antimicrobially processed Sorin Reply SR pacemaker.
Table 2 Silver concentration in whole blood
Day 1 (ppb) Day 7 (ppb)
Sorin <0.6 2
Medtronic 1 <0.6
St Jude 1 10
Boston 2 2
ppb, parts per billion.
inflammation and small volume of exudate in the pocket 
surrounding this implant.
The tissue surrounding the antimicrobially processed 
pacemaker on the right-hand side of the animal (figure 3) 
has a more vascular capsule (than that in figure 2), as 
evidenced by its redder appearance. The tissues overlying 
the pacemaker appear to be thicker and more inflamed. 
There was also clear exudate within the pocket enclosing 
the pacemaker on this side.
Swabs taken aseptically from the surface of the pace-
maker at retrieval and then microbiologically assessed 
showed no evidence of any bacterial growth, indicating 
that all the pacemakers were located within a sterile 
pocket.
Histological examination of the soft tissue capsules 
surrounding the pacemakers using H&E staining from 
around both antimicrobially processed and non-pro-
cessed control pacemakers showed that the capsules 
surrounding the implants were composed of fibrous 
tissue with some macrophage infiltration, though with no 
evidence of any plasma cells. The fibrous tissue was well 
aligned and parallel to the surface of the capsules and in 
many instances was producing a well-aligned collagenous 
tissue. In other regions of the same pacemakers, and 
indeed in other pacemakers, irrespective of whether they 
were antimicrobially processed or control devices, a layer 
of macrophages could be observed at the surface of the 
tissue adjacent to the implant. The surface of the capsule 
adjacent to the antimicrobially processed pacemaker 
or untreated pacemaker is composed of macrophages, 
whereas deeper in the capsule, the layer is composed of 
more fibroblasts.
In places, a brown flaky material is seen within macro-
phages, often adjacent to blood vessels in the capsule 
surrounding both surface processed and non-processed 
control pacemakers. EDX confirmed that this mate-
rial was composed of iron and was likely a breakdown 
product of haemoglobin, often referred to as haemo-
siderin. There was no evidence of any silver-containing 
particles in the capsule tissue surrounding the antimicro-
bially processed pacemakers, using EDX.
The quantification of the interface surrounding all the 
pacemakers by measuring the thickness of the capsule 
and a comparison made between the tissues surrounding 
antimicrobial processed and control pacemakers indi-
cated the average thickness for these samples was in 
the range 500–700 µm. There was no difference in the 
average capsule thickness surrounding the antimicrobial 
processed and control pacemakers (p=0.937; Mann-
Whitney U non-parametric analysis).
The cellularity, vascularity and production/organ-
isation of collagen fibrous tissue scoring used a 
semiqualitative score from 1 to 5, with 1 being low and 
5 being high with five regions of the capsule for each 
pacemaker scored. The average of these scores from the 
six animals was measured for antimicrobially processed 
and control implants, and the mean compared using 
a Mann-Whitney U non-parametric analysis. For all 
measurements, results showed no significant differ-
ence between antimicrobially processed and control 
pacemakers (cellularity: p=0.81; vascularity: p=0.132; 
collagen: p=0.81).
There was no significant difference in the number of 
macrophages in fields of view in capsules surrounding 
antimicrobially processed and control pacemakers. Due 
to the different structure of the capsules between sheep, 
the data show a large interquartile spread of the data for 
both groups with micrographs showing the variability of 
the tissues surrounding the pacemakers. The number 
of macrophages within the capsules was also variable. In 
tissues from around both antimicrobially processed and 
control pacemakers, macrophages tended to be more 
prominent in number towards the surface of the capsule.
Silver analysis of whole blood at 7 days found that levels 
were a maximum of 10 ppb (parts per billion) for one 
sample, more typically ≤2 ppb, compared with <<2 ppb 
for preimplantation levels (see table 2, limit of detec-
tion 0.6 ppb). Only day 1 and day 7 blood samples were 
analysed, as supporting elution studies have shown that 
silver ion release is most rapid in the first few hours and 
days, followed by an exponential fall off over a period of 
weeks to months to below detectable limits. These levels 
are considerably below reported clinical and toxic levels 
based on cellular response.13
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Table 3 Silver concentration in local tissue
Tissue (ppm)
Sorin 0.39
Medtronic 2.4
St Jude 2.7
Boston 0.2
ppm, parts per million.
Local tissue silver concentrations were in a range 
between 0.2 and 2.7 ppm and similar to that reported in 
the literature13 and were not associated with any indica-
tions of toxicity (see table 3, limit of detection 0.01 ppm).
Although not detected using EDX (which may not have 
been sufficiently sensitive to detect the low concentration 
of silver), acid extraction and ICP-MS suggested that 
~20% of the original silver loading was residual on the 
pacemaker titanium surfaces after 12 weeks of implan-
tation.
DISCUSSION
This study presents an in vivo ovine model demonstrating 
feasibility of a silver ion-based antimicrobial surface treat-
ment on pacemakers while maintaining pacing function 
at 12 weeks. The study also provides preliminary evidence 
of the biocompatibility of the surface treatment, recog-
nising the small sample size used in this proof of concept 
study. This study showed no detectable difference 
between control and antimicrobially processed pace-
makers with respect to the titanium and tissue reactivity 
in a prolonged ovine model simulating human pacing 
conditions using devices from four different manufac-
turers. The antimicrobially processed pacemakers did 
not affect the biocompatibility of the pacemakers used 
in this small study, and none of the implants became 
infected, despite being exposed to a prolonged in vivo 
model allowing natural bacterial colonisation. There was 
no difference in the tissue response (control and anti-
microbially processed pacemakers), as judged by the 
appearance of the postmortem capsule and by analysing 
the capsule using histology. Semiquantitative scores 
for cellularity, vascularity and collagen production in 
the capsule showed no significant difference between 
antimicrobially processed and control pacemakers. 
Furthermore, qualitative measurements of the capsule 
thickness showed that there was no difference between 
antimicrobially processed and control pacemakers.
Quantitative measurements of the number of macro-
phages within the capsule were variable, though overall 
there was no difference in the capsules surrounding the 
antimicrobial processed and control implants. Twelve 
weeks appear to be a reasonable experimental time for 
firm tissue healing and complete and stable capsule 
formation with vascularisation. Although not the subject 
of this study, the model could be considered relevant to 
cases of reimplantation, where device-related infection 
may be of enhanced concern, as there appears to be no 
negative effect on biocompatibility in the capsule. The 
ovine model is feasible for pacing studies using the same 
subject for both active and control implants. Our strict 
surgical and pacing processes appear to be a sound struc-
tured investigative approach to measure for infection 
and healing processes. The only additional stage would 
be to implant the electrode into the heart via a suitable 
central vein to more closely simulate human conditions 
and to test for defibrillator activity of ICDs used, sensing 
parameters and lowest pacing thresholds. There are no 
non-standard techniques or additional materials required 
when handling the antimicrobial pacemaker during 
implantation. This is in contrast to the approach used 
by Medtronic and their TYRX antibacterial envelope, 
which is an additional material to handle and manipu-
late during implantation of the pacemaker. The silver 
ion-based surface treatment has the potential to provide 
a broader antimicrobial spectrum than the minocycline 
and rifampicin antibiotic combination used on the anti-
bacterial envelope.
Whereas there was no evidence of any silver remaining 
on the implant surface (nor within any of the capsules) 
using EDX, acid  extraction and ICP-MS analysis esti-
mated ~20% silver remaining on the pacemaker surface 
with no evidence of local colonisation, that is biofilm. 
This is consistent with in vitro elution studies performed 
using this silver ion antimicrobial surface, which shows 
an initial burst release of silver that then reduces in expo-
nential manner over a period of weeks to months. The 
elution rate is to a large extent controlled by the buff-
ering effect of insoluble silver chloride, limiting the 
local concentration of silver to well below reported toxic 
levels.
There were a number of limitations with this study. 
There were no infections observed in either device group 
suggesting the antimicrobial pacemaker surface was no 
worse than control, but no statistical claim can be made 
with regard to antimicrobial effectiveness or biocompat-
ibility as numbers of subjects were small in this proof of 
concept study. Although this was not the primary focus 
of study, an in vivo infection model is conceivable that 
adds a controlled inoculum level into the implant pocket, 
and the viable bacteria count is quantified at a defined 
time point. Such an in vivo study model has previously 
been performed using small inoculated disc samples 
and demonstrated a statistically significant reduction 
in viable bacteria count for the silver ion antimicrobial 
surface. Although the current study used four different 
manufacturers’ pacemakers, the number of devices used 
was low, of simpler complexity (single chamber, basic 
pacemakers) and was relatively short term, so did not 
investigate the effects of long-term pacemaker implanta-
tion. The number of blood and tissue samples analysed 
for silver content were limited, and no statistical claims 
can be made in this proof of concept study. We did not 
place the lead into veins or allow sensing functions to 
be tested or remote unipolar mode pacing as the leads 
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were not intracardiac. Pacing times were also somewhat 
shorter without need for initial radiology imaging, and 
retrieval of the device and electrodes was simpler than 
human settings.14
Whereas the assessment of inflammatory effects of 
implants on the cells at the interface was by commonly 
used morphological characterisation, more definitive 
analysis could have been made by using immunohisto-
chemistry to identify macrophages and various types of 
plasma cells.
CONCLUSIONS
This study confirms the biocompatibility and feasibility of 
applying the same silver ion-based antimicrobial surface 
technology to a titanium pacemaker surface while main-
taining pacing function in a robust and unique ovine 
model over a follow-up of 12 weeks. This promising new 
approach does not change standard pacemaker implant 
techniques, adds no procedural delays and is worth-
while researching further to tackle the growing problem 
of implantable cardiac electronic implantable device 
infection rates. Previous studies have demonstrated that 
this silver ion-based antimicrobial surface technology 
(Agluna) is proving to be safe and clinically effective 
in reducing the incidence of infection in limb salvage 
surgery. This positive clinical experience, along with the 
current study, provides confidence that applying this 
surface treatment to pacemakers in a clinical applica-
tion is a feasible route forwards to take the product to 
market.
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